Flagship’s Repertoire combines Cogen, Torque to pick antigens for immunotherapies

By combining TCR-antigen matching company Cogen with T cell therapy play Torque, Flagship Pioneering’s Repertoire Immune Medicines Inc. aims to boost the latter’s ongoing oncology programs while demonstrating clinical proof of concept for the former’s platform.

Flagship CEO and Repertoire co-founder Noubar Afeyan told BioCentury Cogen Immune Medicine Inc.’s technology, which also has traction in autoimmunity and infectious disease, could eventually be applied to therapeutic modalities beyond Torque Therapeutics Inc.’s cytokine-tethered, primed T cells, such as genetically engineered cells, vaccines, and T cell-depleting agents -- either in-house, or via partnerships...